3rdPartyFeeds News

Dow Jones Newswires: Roche extends tender offer for Spark Therapeutics

The period for Roche’s offer of $114.50 per share for U.S.-based Spark has been extended several times and was set to expire on Dec. 10. Read More...

Roche Holding AG said the offer was extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their reviews of the pending acquisition.

The period for Roche’s ROG, +0.28% offer of $114.50 per share has been extended several times and was set to expire on Dec. 10.

As of Dec. 6, around 14.9% of Spark’s ONCE, +0.88%  outstanding shares had been tendered, according to Roche.

Read More

Add Comment

Click here to post a comment